Ahmet Murat Aydın

Assistant Professor

UAMS

Also affiliated: The University of Texas MD Anderson Cancer Center (1995); Istanbul Aydın University (1999); Moffitt Cancer Center (2019–2025); Istanbul University-Cerrahpaşa (1999–2011); Hacettepe University (2011–2024); Istanbul University (1999–2011); The University of Texas Southwestern Medical Center (2017–2020); University of Tampa (2020)

Faculty Researcher

18 h-index 95 pubs 805 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Ahmet Murat Aydın is an Assistant Professor at the University of Arkansas for Medical Sciences whose research focuses on cancer biology and treatment outcomes. His work investigates the spatial distribution of immune cells within tumors, such as CD68+ tumor-associated macrophages and cancer-associated fibroblasts, and their correlation with patient survival in metastatic clear cell renal cell carcinoma. Aydın also studies tumor-infiltrating lymphocytes (TILs) in penile and bladder cancers, exploring factors that influence their expansion and potential therapeutic applications.

His research also examines the relationship between immune cell infiltration patterns and somatic mutations in advanced clear cell renal cell carcinoma. He has published on the concept of oncogenesis recapitulating embryogenesis and its implications for cancer care. Additionally, Aydın has contributed to studies on treatment protocols for muscle-invasive bladder cancer and the validation of artificial intelligence algorithms for prostate cancer detection using MRI.

Metrics

h-index: 18
Publications: 95
Citations: 805

Selected Publications

Editorial Comment (2026)

The Journal of Urology DOI OpenAlex
Impact of intraoperative intravenous heparin bolus on clinical outcomes during radical nephrectomy and IVC tumor thrombectomy in renal cell carcinoma with level I–IV IVC thrombus: A multi-institutional study (2026)

Urologic Oncology Seminars and Original Investigations DOI OpenAlex
A call for raising public awareness and improving outcomes of penile cancer (2025)

Cancer 1 citation DOI OpenAlex
Response to the Letter on MRI in Prostate Cancer Screening and Clinical Trial Requirements (2025)

Academic Radiology DOI OpenAlex
External Validation of an Artificial Intelligence Algorithm Using Biparametric MRI and Its Simulated Integration with Conventional PI-RADS for Prostate Cancer Detection (2025)

Academic Radiology 7 citations DOI OpenAlex
Minimally Invasive Management of Inguinal Lymph Nodes in Penile Cancer: Recent Progress and Remaining Challenges (2024)

Cancers 4 citations DOI OpenAlex
Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer (2024)

Journal of Clinical Medicine 2 citations DOI OpenAlex
Abstract A020: An early determination of patients eligibility for a bladder cancer immunotherapy using a data science approach (2024)

Cancer Research DOI OpenAlex
Identification of a panel of microRNA biomarkers for the management of patients with refractory germ cell tumor of the testis. (2024)

Journal of Clinical Oncology 1 citation DOI OpenAlex
Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report (2023)

BMC Urology 2 citations DOI OpenAlex
Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care (2023)

Cancers 1 citation DOI OpenAlex
Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy (2023)

Cancers 2 citations DOI OpenAlex
Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care (2023)

Cancers 6 citations DOI OpenAlex
Abstract B015: Racial differences in epigenetic aging and its impact on expression of T-cell inhibitory receptors (2023)

Cancer Research DOI OpenAlex
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer (2022)

Urologic Oncology Seminars and Original Investigations 6 citations DOI OpenAlex